Clinical Trial Search

Primary: Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy…

Primary: Number of Participants Categorized by RTOG Grading Scale — 12; 6; 11; 11 Participants

Primary: Number of Participant With Neutrophil Recovery — 78 Participants

Primary: Severity of Dermatitis in Radiation Treatment Site in Breast Cancer Patients — 2.6; 3.4 units on a scale — p=0.0077

Primary: Number of Excess Double-strand DNA Break Foci Per Cell in Peripheral Blood Samples Post-imaging — 0.183; 0.159 gamma-H2AX foci in blood lymphocytes — p=<0.05

Primary: Number of Participants Whom Received Medihoney Treatment and Were Analyzed Weekly for Skin Changes While Undergoing Radiation Therapy — 15; 15; 15; 15 participants

Primary: Number of Participants With Late Effects > 3 Months Post RT — 20 Participants

Primary: Change in Bone Mineral Density (Tb. BMD) — 4.5; -39.3; -8.7; -54.7 mg/cm^3

Primary: Incidence of Early Adverse Skin Reactions (EASRs) — 13; 10; 4; 6 Participants

Primary: Grade 3 or Higher Adverse Events — 9 Participants

Primary: Number of Participants With an Adverse Skin Event — 1 Participants

Primary: Number of Participants With Radiation Pneumonitis — 8; 10 participants — p=0.05

Primary: Tissue Oxygenation — 62.5 mmHg — p=0.5

Primary: Percentage of Participants With Physician Reported Rectal Toxicity ≥ Grade 2 During the First 2 Years of Radiation Treatment — 38 percentage of participants — p=0.9138

Primary: Proportion of Patients Without Grade G2 Skin Toxicity Radiodermatitis at Week 5 — 10; 5; 13; 11 participants

Primary: Clinical Oral Mucosal Injury Score at Cumulative Radiation Dose of 5000 cGy — 1.42; 1.36 units on a scale

Primary: Percent of Women Who Develop Grade 3 or 4 Radiation Dermatitis (as Defined by the Stanford Radiation Dermatitis Scoring System) During a Course of Radiation Therapy — 6…

Primary: Incidence of Implant Failure — 8; 17; 34; 41 Number of Participants with Implant Fail

Primary: Radiation Dermatitis — 34; 36 Participants — p=.8872

Primary: Operator Radiation Exposure — .65; .56 mSv

Primary: Mean Radiation Dermatitis Severity Score — 2.02; 1.99 units on a scale — p=0.6555

Primary: Number of Proteins Expressed Differently in Response to Receiving Radiation Therapy — 31 Proteins

Primary: Number of Patients With an Acceptable Level of Severe Toxicity as Defined at < Grade 3 CTC Toxicity — 20 participants

Primary: Radiation Therapy Oncology Group Skin Toxicity Scoring — 0.00; 0.00; 0.09; 0.15 score on a scale

Primary: Number of Participants With Grade ≥2 Radiation Dermatitis at 50 Gy (Per Protocol Set) — 3; 9; 6; 18 Participants

Primary: Completion Rate of Use of KeraStat Cream — 10; 7 Participants

Primary: 2-year Local Recurrence Rate (LRR)/Incidence of Local Recurrence — 10 percentage of patients with LR

Primary: Success Rate — 65.4 percentage of participants

Primary: Number of Participants Who Received PET/CT and MRI Perfusion Studies — 53; 95 Participants

Primary: Dose-limiting Toxicity (DLT) — 0; 0; 0; 0 Participants